AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02233829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Reactivity
Description: IV methylphenidate, used under IND #124, 912 is injected into the subject s bloodstream to be used in conjunction with PET imaging to show displacement of \[11C\]raclopride.
Study NCT02233829 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Brain Dopamine Receptor
Description: The radiotracer \[11C\] raclopride is used for imaging dopamine receptors and dopamine release.
Study NCT05415319 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Laboratory tasks in middle childhood/pre-adolescence
Description: Children will watch a 2-minute clip from a live-action movie and complete Storytelling and Mask tasks from the Laboratory Temperament Assessment Battery.
Study NCT06340542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Mobility exercises
Description: Exercises which focus on improve the mobility of the spine especially thoracic region was administered to the patients in different position including quadruped and standing position.
Study NCT06340542 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Release technique
Description: Interventions include release the muscle tension, trigger point release and reducing stiffness of spine was administered
Study NCT05048901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Oral Cabozantinib 40-60 mg daily .every 4 weeks as a cycle
Study NCT05048901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide 120 mg deep SC on day 1 every 4 weeks.every 4 weeks as a cycle
Study NCT05236205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Caries removal with a lowspeed drill
Description: 1. Initial periapical and interproximal radiographs;~2. Prophylaxis with toothbrush and fluoride toothpaste;~3. Relative isolation with lip bumper, cotton roll, and aspirator;~4. Microbiological sampling with ear curette for standardization of volume of carious tissue;~5. Removal of carious dentin with carbide burs and manual instruments;~6. Additional microbiological sampling;~7. Clinical inspection of texture of remaining dentin with an exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar Easy Mix - 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months.
Study NCT05236205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ for 5 m inutes, removal of carious tissue around lateral walls of the cavity with noncutting curette and no removal of carious tissue on pulp floor;~5. Second microbiological sample of remaining dentin with curette;~6. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~7. Restoration with glass ionomer cement;~8. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.
Study NCT05236205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™ and application of Bixa Orellana extract (20%)
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes, removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement;~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.
Study NCT05236205 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial removal of carious tissue with the administration of Papacarie™, application of Bixa Orellana extract (20%) and LED (aPDT)
Description: 1. Initial radiographs;~2. Relative isolation;~3. Microbiological sample with otoscope curette to standardize volume of carious tissue;~4. Application of Papacarie™ with Bixa Orellana extract (20%) for 5 minutes and the blue light-emitting diode (LED) irradiation with 440-480 nm. Removal of carious tissue around lateral walls of the cavity with noncutting curette;~5. Irradiation of dental tissue for 1 minute on a single point;~6. Second microbiological sample of remaining dentin with curette;~7. Clinical evaluation by inspection of texture of remaining dentin with exploratory probe;~8. Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);~9. Clinical and radiographic follow-up immediately, 1 week, 1, 3, 6, and 12 months after treatment.
Study NCT04553939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 3mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
Study NCT04553939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 800mg/m2 ivgtt, D1 every 14 days for 2-4 cycles.
Study NCT04771286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550 (C-14)
Description: BI 1015550 (C-14)
Study NCT05495282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microvideo
Description: Asynchronous 10-minute micro-video on the topic for which no face-to-face interaction with faculty will be conducted.
Study NCT05849727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3821 tablets 200 mg
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
Study NCT05849727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets 200 mg
Description: TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
Study NCT04892966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TXI Light Imaging
Description: Standard Colonoscopy using TXI imaging
Study NCT04892966 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: WLI Imaging
Description: Standard Colonoscopy using White Light Imaging
Study NCT05139654 — intervention group
Intervention type: OTHER
Intervention: Arm elevation in the scapular plane
Description: Lift the arm up in the scapular plane
Study NCT05139654 — intervention group
Intervention type: OTHER
Intervention: Pull up with gymbar
Description: Grasp the gymbar with both hands and pull up as high as the subject can
Study NCT05139654 — intervention group
Intervention type: OTHER
Intervention: Pull up with fingerboard
Description: The width of the fingerboar is 20 mm. Pull up with fingers on the fingerboard.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib is in the form of oral capsules. Palbociclib, capsule, 125 mg taken orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days. Palbociclib should be taken with food
Study NCT04961229 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The Pfizer mRNA-based BNT162b2 vaccine
Description: participants who gave informed consent to participate in either the prospective non-randomised study or RCT will receive a single vaccine dose.~In addition, participants in the RCT will be randomised into two groups:~1. Third booster dose of BNT162b2 (one standard dose) with no change in immunosuppression protocol~2. Third booster dose of BNT162b2 (one standard dose) with immunosuppression reduction according to protocol (mycophenolic temporary cessation 4 days before (5 half-lives) and one week (expected antibody response) after vaccination (to allow for antibody response).
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Ribociclib
Description: Ribociclib, tablets, 600mg orally (three 200 mg tablets)taken once daily with or without food for 21 consecutive days followed by 7 days off treatment
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Abemaciclib
Description: Abemaciclib in combination with fulvestrant or an aromatase inhibitor: 150 mg twice daily Abemaciclib as monotherapy: 200 mg twice daily. (2.1)
Study NCT05064202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella 5.5
Description: temporary Mechanical Circulatory Support (tMCS)
Study NCT05064202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inotropes
Description: Enoximone, Dobutamine, Dopamine, Milrinone
Study NCT05198115 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training for 8 weeks, 3 times a week, and 60 min each time
Study NCT05198115 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: aerobic training for 8 weeks, 3 times a week, and 60 min each time
Study NCT04976868 — intervention group
Intervention type: DRUG
Intervention: Pimecrolimus 1% Top Cream
Description: Elidel® as prescribed within routine clinical practice
Study NCT05548218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated health education using a digital health pathway
Description: MyChart Care Companion is an interactive, individualized plan of care delivered to at-risk patients through user-friendly, accessible technology. Care Companion is a digital health pathway housed within EPIC. Care Companion features are integrated into the existing MyChart mobile app, which is part of Epic, and is available for iOS and Android devices. The interactive plan of care delivers notifications to patients' phones, prompts patients to complete educational session in the mobile app, analyzes questionnaire responses and patient-reported data, and orchestrates changes to the plan and escalations as needed to help patients, their caregivers, and care managers stay on top of the patient care. In addition to mobile phone, patients can also now access MyChart Care Companion on webpages via computers. The automated pathway assigns patient interactive health education materials during the study.
Study NCT04863456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total resection
Description: Total resection of HIPA in a single surgery
Study NCT04863456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staged resection
Description: HIPA was resected subtotally at first time, and the tumor remnant was removed at a later date
Study NCT04863456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subtotal resection followed by stereotactic radiation therapy
Description: HIPA was resected subtotally at first time, and the tumor remnant was controled by the stereotactic radiation therapy
Study NCT06526871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser acceleration
Description: This intervention involves the application of Low-Level Laser Therapy (LLLT) using the Epic X device for patients undergoing orthodontic treatment. The protocol is designed to assess the effects of LLLT on pain reduction and treatment efficacy during the initial leveling and alignment phase of orthodontic therapy using clear aligners .
Study NCT06526871 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clear aligner therapy
Description: Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
Study NCT06526871 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: clear aligner therapy
Description: Clear aligner therapy involves using a series of custom-made, clear plastic aligners to gradually move teeth into their desired positions. These aligners are worn over the teeth and are typically changed every week as the teeth gradually shift. The treatment process starts with a digital scan or impression of the teeth, which is used to create a 3D model. This model helps in planning the precise movements needed to achieve proper alignment. Throughout the treatment, patients visit their orthodontist periodically to monitor progress and receive new sets of aligners. Clear aligners are popular for their aesthetic appeal and the convenience they offer compared to traditional braces.
Study NCT06530290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 MG
Description: Mirtazapine (15 mg), once a day for 12 weeks
Study NCT06530290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once a day, for 12 weeks
Study NCT05895981 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: G132 system, Beijing PINS Medical Co., China
Description: Neuromodulation was performed according to the usual protocol
Study NCT04829279 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CONNECT AI system group
Description: A. During the Intervention period, paramedics wear equipment for multi-faceted data acquisition and press the start button of the system.~B. During the Intervention period, inside the ambulance, a application that implements a function that automatically evaluates the patient's severity, displays a list of optimal transfer hospitals based on this, and shares real-time information of the hospitals, is installed so that paramedics can refer to the work.~C. ED's medical staff will receive through ER-kiosk pre-hospital patient information collected and analyzed through the CONNECT AI system before arrival.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole will be dosed daily at a fixed dose of 2.5 mg/day throughout the study.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Anastrozole
Description: Anastrozole will be dosed daily at a fixed dose of 1 mg/day throughout the study.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Tamoxifen
Description: Tamoxifen will be dosed daily at a fixed dose of 20 mg/day throughout the study.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: Fulvestrant is in the form of a prefilled syringe containing 5 ml of an injection solution of 250 mg of fulvestrant for intramuscular injection. The recommended dose is once every 28 days, once at a dose of 500 mg, and on the 15th day after the initial injection, a loading dose of fulvestrant 500 mg is added.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Exemestane
Description: Exemestane will be dosed daily at a fixed dose of 25mg/day throughout the study.
Study NCT04852081 — intervention group
Intervention type: DRUG
Intervention: Alpelisib
Description: Alpelisib will be dosed daily at a fixed dose of 300 mg/day throughout the study.
Study NCT06204172 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intensive Neurowave Emotional Stimulation (INES)
Description: Patients will undergo Neurowave-assisted multisensory stimulation five days a week for four weeks, featuring emotionally significant audio-visual content tied to personal history. Control group participants will experience primary auditory stimulation through familiar sounds, following a traditional rehabilitation approach mimicking the experimental group's frequency and intensity but without Neurowave use. This allows for a meaningful comparison of the two groups' experiences.
Study NCT06204172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Sensorial Emotional Stimulation (ISES)
Description: The Intensive Sensorial Emotional Stimulation (ISES) in the control group involves primary auditory stimulation with emotionally rich everyday sounds, including familiar voices, favorite songs, and sounds related to daily life and past activities. It mimics the experimental group's frequency and intensity, lasting 45 minutes per session, five days a week, for four weeks. Unlike the experimental group using Neurowave, the control group follows a traditional rehabilitation approach with paper materials, live photos, face-to-face interaction, and classic music tapes, facilitating a meaningful comparison between the two groups' experiences.
Study NCT05849727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3821 tablets matching placebo
Description: TQH3821 tablets matching placebo without active substance.
Study NCT05155826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Headset
Description: The patient will benefit from the placement of Cook's balloon (standard care) with the placement of the virtual reality headset on the examination table with the launch of the software before the beginning of the procedure. The virtual reality helmet will be removed at the end of the procedure.
Study NCT06447220 — intervention group
Intervention type: DRUG
Intervention: washed microbiota transplantation
Description: The prepared microbiota suspension was infused into the patients' gut.
Study NCT06407895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Limb Fitness Program
Description: the stability of the core area can help to improve dynamic balance, coordinate the upper and lower trunk muscles, and reduce muscles' damage and abnormalities. Physiotherapy had a role in programming training for Down Syndrome children, for example, using squat to stand training that seemed to improving lower extremity muscle power. Squat-to-stand training will stimulate the proprioceptive stimulation on the trunk and lower extremity
Study NCT06407895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Therapy
Description: In control group routine therapy will be given 3 times a week for 6 weeks with session conducting 45 minutes per sessions which involve standing balance exercises, sitting from chair to stand, heal to toe stand will be performed.
Study NCT05472285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Verum
Description: After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
Study NCT05472285 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization (visit V1), subjects will consume orally 2 capsules per day, during the breakfast, for 8 weeks (from visit V1 to visit V3).
Study NCT06496906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tooth extraction
Description: A regular closed tooth extraction was performed with the different devices from each arm.
Study NCT06496906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tooth extraction
Description: A regular closed tooth extraction was performed with the different devices from each arm.
Study NCT06496906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Benex
Description: Benex was used to perform the intervention.
Study NCT06496906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physics Forceps
Description: Physics forceps were used to perform the intervention.
Study NCT06496906 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Extraction Forceps
Description: Conventional Extraction Forceps were used to perform the intervention.
Study NCT06528353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV16-E6 serology and HPV ctDNA
Description: In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance.
Study NCT06528353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV16-E6 serology and HPV ctDNA
Description: In the event of a malignant lesion identified on clinical examination and/or imaging, treatment will be performed according to the standard of care. In the absence of any suspicious lesion, but in the event of HPV ctDNA positivity, prophylactic surgery of the tonsils and base of the tongue (the vast majority of HPV-related OPC develop in these regions) will be proposed to the patient, given the high risk of OPC. In case of refusal of this prophylactic surgery, close clinical and imaging monitoring will be performed.~Surgical specimens will be analyzed to confirm or not the presence of HPV-driven OPC and HPV ctDNA will be measured post-operatively to ensure disease clearance.
Study NCT06322472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Turkish Early Language Development Test (TEDIL)
Description: The Turkish Early Language Development Test (TEDIL) is a test that measures the receptive and expressive language skills of children between the ages of 2 and 7 years and 11 months.
Study NCT06322472 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: The Family Literacy Scale
Description: The Family Literacy Scale, which is a reliable and valid measurement scale, was developed by Kılıç, Doğan, and Özden (Kılıç, Doğan, and Özden 2017). The items of the scale consist of questions about parental literacy, child literacy, and early literacy. Parental Literacy Scale to identify and analyse situations such as the use of literacy skills, role modelling for children, performing simple literacy activities at home, on the street, etc. and generally helping children to learn to read and write.